National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer
HPB · 2023
DOI: 10.1016/j.hpb.2023.06.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift HPB, 2023. Verfasst von Ibrahim Nassour und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Surgical Oncology, University of Florida, Gainesville, FL, USA. Electronic address: Nassour.ibrahim@gmail.com. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoadjuvant Therapy, Practice Patterns, Physicians', Pancreatectomy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: The historical standard of care in treating operable pancreatic cancer via upfront surgery has been challenged recently using a neoadjuvant approach. The aim of the study is to examine the national practice patterns in the management of pancreatic cancer with an emphasis on the trends of neoadjuvant systemic therapy use. METHODS: This is a cross-sectional time-series study using the National Cancer Database from 2006 to 2019. Patients who underwent resection for stage I-II pancreatic adenocarcinoma were selected. RESULTS: Overall, 25% of patients had neoadjuvant chemotherapy, 49% had surgery followed by adjuvant chemotherapy and 26% had surgery alone. The rate of neoadjuvant chemotherapy has increased from 11% in 2006 to 43% in 2019. There was a decrease in the rate of surgery followed by chemotherapy from 48% to 38%, and a decrease in the rate of surgery alone from 41% to 19%. The rate of radiation therapy use has decreased over time, as has the resection rate, while median overall survival has steadily improved over the years. CONCLUSIONS: In 2019, the rate of using neoadjuvant systemic therapy overtook the rate of surgery first followed by adjuvant systemic therapy, marking a pragmatic national shift in the clinical management of pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, Division of Surgical Oncology, University of Florida, Gainesville, FL, USA. Electronic address: Nassour.ibrahim@gmail.com.
- Department of Surgery, Division of Surgical Oncology, University of Florida, Gainesville, FL, USA.
- Department of Medicine, Division of Hematology & Oncology, University of Florida, Gainesville, FL, USA.
- Department of Radiation Oncology, University of Florida, Gainesville, FL, USA.
- Department of Surgery, Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Zitieren
APA
Nassour, I., Parrish, A., Baptist, L., Voskamp, S., Handoo, K., Rogers, S., Fabregas, J., George, T., Hitchcock, K., Paniccia, A., & Hughes, S. (2023). National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. HPB. https://doi.org/10.1016/j.hpb.2023.06.018
Vancouver
Nassour I, Parrish A, Baptist L, Voskamp S, Handoo K, Rogers S, et al. National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. HPB. 2023. doi:10.1016/j.hpb.2023.06.018
BibTeX
@article{Nassour2023,
author = {Nassour, Ibrahim and Parrish, Austin and Baptist, Lucy and Voskamp, Sarah and Handoo, Komal and Rogers, Sherise and Fabregas, Jesus and George, Thomas and Hitchcock, Kathryn and Paniccia, Alessandro and Hughes, Steven},
title = {National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer},
journal = {HPB},
year = {2023},
doi = {10.1016/j.hpb.2023.06.018}
}
EUVIMED